Adrenocortical Carcinoma (ACC) is a rare and aggressive form of cancer that originates in the adrenal cortex, which is responsible for producing vital hormones such as cortisol, aldosterone, and androgens. Due to its rapid growth, late-stage diagnosis, and limited treatment options, ACC typically has a poor prognosis. Symptoms often do not appear early, but as the disease progresses, patients may experience abdominal pain, unexplained weight loss, high blood pressure, and hormonal imbalances. Early detection and tailored interventions according to the disease stage are crucial to improving patient outcomes and survival.

Epidemiological Segmentation of ACC (2020–2034) – 7MM

Total Number of Incident Cases

The number of ACC cases is expected to rise steadily across the 7 major markets (7MM) from 2020 to 2034.

Stage-wise Distribution of Cases

• In the US, the largest proportion of ACC cases were Stage III (38%), followed by Stage IV (27%), Stage II (20%), and Stage I (15%).
  
  

Gender-based Incidence

ACC is more prevalent in females (60%) compared to males (40%).

Age-specific Incidence

• In the EU4 and the UK, the highest incidence was found in the 41–60 age group (53%).
  
  

• A small proportion of cases (3%) were in patients under 20 years old.

See the full picture—explore our latest infographic now!: Click Here

2023 Epidemiology Highlights

• In 2023, approximately 1,200 new ACC cases were reported across the 7MM, with numbers expected to grow through 2034.
  
  

• The United States had the highest number of cases, with around 450 reported.
  
  

• Within the EU4 and the UK, Germany had the highest incidence (~160 cases), while Spain had the lowest (~80 cases).
  
  

See the full picture—explore our latest infographic now!: Click Here

Adrenocortical Carcinoma Market Overview

The market size for ACC treatment across the 7MM was estimated at USD 22.4 million in 2023.

Market Drivers

• Progress in immunotherapy and targeted combination treatments is improving the treatment landscape.
  
  

• Increased awareness, better diagnostic methods, and greater access to clinical trials are contributing to improved detection and treatment uptake.

Market Challenges

• The rarity of ACC limits the ability to conduct large-scale clinical trials, leading to a shortage of comprehensive clinical data.
  
  

• High treatment costs and limited insurance coverage make access to innovative therapies difficult for many patients.

Explore key stats, market drivers, and emerging drugs—all in one visual!

https://www.delveinsight.com/infographics/adrenocortical-carcinoma-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr

Emerging Therapies

• EO2401 + Nivolumab: A combination therapy showing promise in treatment.
  
  

• Additional investigational drugs are also in development.
  
  

Key Industry Players

• HRA Pharma
  
  

• Takeda Pharmaceuticals
  
  

• Pfizer Inc.
  
  

• Novartis AG
  
  

• Bayer AG
  
  

• Bristol-Myers Squibb Company
  
  

• Ipsen Biopharmaceuticals, Inc.
  
  

• Exelixis, Inc.
  
  

• Genentech, Inc.
  
  

• Merck KGaA
  
  

• And others